pubmed-article:15143463 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0079522 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0700364 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C1442488 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C1442473 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0231175 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0205165 | lld:lifeskim |
pubmed-article:15143463 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
pubmed-article:15143463 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:15143463 | pubmed:dateCreated | 2004-5-14 | lld:pubmed |
pubmed-article:15143463 | pubmed:abstractText | The association between minor mutations in human immunodeficiency virus (HIV) protease at baseline and development of common primary mutation 90M at virological failure (conferring some resistance to all protease inhibitors [PIs]) was evaluated in 93 previously drug-naive patients experiencing failure of their first PI-based antiretroviral regimens. In logistic regression analysis, the probability of accumulating a new 90M mutation at virological failure was associated with the presence at baseline of minor mutation 36I (naturally occurring in approximately 25% of HIV clade B and in >80% of HIV non-clade-B viruses) (adjusted odds ratio, 13.5 [95% confidence interval, 1.89-95.6]; P=.009) and, possibly, of 10I/V. This suggests a potential role for the presence of 36I at baseline in predicting the appearance of 90M at virological failure. | lld:pubmed |
pubmed-article:15143463 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:language | eng | lld:pubmed |
pubmed-article:15143463 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:15143463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15143463 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15143463 | pubmed:month | Jun | lld:pubmed |
pubmed-article:15143463 | pubmed:issn | 0022-1899 | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:BerrierJJ | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:d'Arminio... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:ChirianniAnto... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:Cozzi-LepriAl... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:PernoCarlo... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:BalottaClaudi... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:ViolinMichela... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:OraniAnnaA | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:ForbiciFederi... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:Italian... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:De... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:Stella... | lld:pubmed |
pubmed-article:15143463 | pubmed:author | pubmed-author:CadeoGiampier... | lld:pubmed |
pubmed-article:15143463 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15143463 | pubmed:day | 1 | lld:pubmed |
pubmed-article:15143463 | pubmed:volume | 189 | lld:pubmed |
pubmed-article:15143463 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15143463 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15143463 | pubmed:pagination | 1983-7 | lld:pubmed |
pubmed-article:15143463 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:meshHeading | pubmed-meshheading:15143463... | lld:pubmed |
pubmed-article:15143463 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:15143463 | pubmed:articleTitle | Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. | lld:pubmed |
pubmed-article:15143463 | pubmed:affiliation | Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, University of Rome Tor Vergata, Italy. cf.perno@uniroma2.it | lld:pubmed |
pubmed-article:15143463 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15143463 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15143463 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15143463 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15143463 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15143463 | lld:pubmed |